HALO stock forecast, quote, news & analysis
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more
Why Halozyme Therapeutics (HALO) Stock Is Up +30.1% in the Last 30 Days
Key Takeaways
- HALO shares advanced approximately 30.1% during the 30 days ended August 14, 2026, based on an available price of $98.63 versus a closing price of $75.82 on July 15.
- The move was driven primarily by second-quarter 2026 results released August 6, including revenue of $481 million and non-GAAP diluted EPS of $2.28.
- Management raised full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP EPS.
- Strong ENHANZE royalty growth, five new collaboration agreements, and $332.8 million in second-quarter share repurchases reinforced investor confidence.
- Key risks include Merck patent litigation, partner concentration, and the longer-term execution of the Hypercon platform.
Halozyme Therapeutics (HALO) Company Overview and Market Position
Halozyme Therapeutics, Inc. is a biopharmaceutical drug-delivery company best known for its ENHANZE platform, which uses recombinant human hyaluronidase to enable subcutaneous administration of injectable biologics. The company generates high-margin royalties from partner products that use the technology, while also selling proprietary products including Hylenex and XYOSTED. Major ENHANZE-enabled therapies include subcutaneous DARZALEX, VYVGART Hytrulo, PHESGO, OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT FASPRO.
Halozyme’s business model is built around recurring royalty revenue, a diversified partner base, and expanding applications for drug delivery across oncology, immunology, and neurology. Investors follow the stock closely because royalty streams convert efficiently into cash flow, and the company is positioning its newer Hypercon platform as a second long-term growth engine.
Halozyme Therapeutics (HALO) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 days ended August 14, 2026, HALO rose from a closing price of $75.82 on July 15 to an available price of $98.63, a gain of about 30.1%. The sharpest move occurred after the August 6 earnings release: the stock closed at $85.76 on August 6 and jumped to $103.12 the following session, a one-day increase of roughly 20.2%, before consolidating near $98–$103 in subsequent sessions.
The quarterly trend was even stronger. From a close of $69.21 on May 14, 2026, to $98.63 on August 14, HALO advanced approximately 42.5%. The move reflects a broader re-rating that began after first-quarter results in May and accelerated when second-quarter results and raised guidance confirmed the momentum.
What Drove HALO Stock Price in the Last 30 Days
The main catalyst was Halozyme’s second-quarter 2026 report, released August 6. Total revenue rose 48% year over year to $481 million, royalty revenue increased 50% to $307.7 million, and adjusted EBITDA climbed 46% to $328.8 million. Non-GAAP diluted EPS of $2.28 compared with $1.54 a year earlier and came in well above analyst expectations.
Management also raised full-year 2026 guidance. The company now expects total revenue of $1.835 billion to $1.91 billion, royalty revenue of $1.22 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.28 billion, and non-GAAP diluted EPS of $8.65 to $9.00. Underlying royalty performance supported the outlook: DARZALEX royalties rose 27% to $152.2 million, VYVGART Hytrulo royalties rose 143% to $72.6 million, and royalties from newer launches increased about 80% sequentially.
Additional tailwinds included five collaboration and licensing agreements announced across the second quarter and July, involving partners such as GSK, Incyte, Vertex, and Oruka. These deals generated $35.5 million in upfront collaboration revenue and expanded ENHANZE and Hypercon into areas including antibody-drug conjugates and nucleic acid therapies. Share repurchases of $332.8 million during the quarter also signaled confidence in cash generation and supported per-share metrics.
What Drove HALO Stock Performance Over the Last Quarter
The broader quarterly advance began with first-quarter 2026 results reported May 11. Revenue rose 42% year over year to $376.7 million, royalty revenue increased 43% to $240.7 million, and non-GAAP diluted EPS reached $1.60. Halozyme reaffirmed its 2026 guidance at that time and announced a new $1 billion share repurchase authorization, with at least $400 million expected in 2026.
Through June and July, the stock benefited from sustained commercial uptake of ENHANZE-enabled products, new partnership activity, and progress on Hypercon manufacturing plans. The August earnings beat then validated the trend, showing that royalty growth was broadening beyond DARZALEX and VYVGART into newer subcutaneous launches. The combination of accelerating royalties, higher guidance, and active capital returns turned a steady uptrend into a sharper repricing.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader ecosystem of hundreds of bots that trade thousands of tickers. Only top-performing and most relevant bots appear in this section, making it a useful starting point for traders and investors who want to screen automated strategies rather than build their own from scratch. The bots vary by trading approach, holding period, risk profile, and performance metrics, so the page can support different market conditions and objectives. Because selections are continuously updated based on performance and relevance, readers can review the latest available AI trading tools and evaluate whether automated strategies fit their own research process.
HALO Stock Forecast Drivers: What Investors Should Watch Next
- Partner product momentum: Continued uptake of OCREVUS ZUNOVO, Opdivo Qvantig, RYBREVANT FASPRO, and TECENTRIQ HYBREZA will influence royalty growth and guidance credibility.
- Litigation risk: Halozyme’s patent infringement dispute with MRK remains a key uncertainty, with U.S. patent-review appeals expected to resolve around the end of 2026.
- Pipeline execution: Investors will monitor progress toward 13 ENHANZE development programs by year-end and preparation for first Hypercon clinical studies in 2027.
- Financial updates: Third-quarter 2026 results, updated guidance, and the pace of share repurchases will help determine whether royalty acceleration and margin trends remain intact.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HALO in -3.08% downward trend, sliding for three consecutive days on August 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HALO declined for three days, in of 278 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
HALO broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on HALO as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on July 24, 2026. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 329 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 297 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (84.746) is normal, around the industry mean (20.109). P/E Ratio (31.554) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (7.905) is also within normal values, averaging (445.198).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology